Amarantus Discusses New Independent Peer-Reviewed Research Papers on MANF

SAN FRANCISCO and GENEVA, July 18, Jul 18, 2014 (GLOBE NEWSWIRE via COMTEX) Amarantus Bioscience Holdings, Inc. (OTCQB:AMBS), a biotechnology company focused on the discovery and development of novel diagnostics and therapeutics related to endoplasmic reticulum stress, cell cycle dysregulation, neurodegeneration and apoptosis, today announced that it has updated its MANF publications list with 8 previously undisclosed independent peer-reviewed research papers. The scientific articles include several Chinese publications as well as new publications that have been released since the beginning of 2014. The continual increase in publications on MANF speaks to the uniqueness of MANF s activity and its ability to rescue cells across a spectrum of protein misfolding-related disorders, commented David A. Lowe, PhD, member of the Amarantus Board of Directors. MANF is emerging as an especially interesting scientific target, thereby increasing the value of the Company s intellectual property and
http://bit.ly/1nj5fZy